Dyslipidaemia is associated with testosterone, oestradiol and androgen receptor CAG repeat polymorphism in men with type 2 diabetes

Clinical Endocrinology

Volumn 74, Issue 5, 2011, Pages 624-630

  Stanworth, R D ^a,b   Kapoor, D ^a,b   Channer, K S ^c,d   Jones, T H ^a,b  

^a BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CAG REPEAT; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

AGED; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; ESTRADIOL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN; TESTOSTERONE; TRINUCLEOTIDE REPEATS;

EID: 79953741235     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.03969.x     Document Type: Article

References (31)

1. Kapoor, D., Aldred, H., Clark, S., et al. (2007) Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care, 30, 911-917. (Pubitemid 46556586)
2. Ding, E.L., Song, Y., Malik, V.S., et al. (2006) Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA, 295, 1288-1299.
3. Laaksonen, D.E., Niskanen, L., Punnonen, K., et al. (2004) Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care, 27, 1036-1041. (Pubitemid 38579762)
4. Stellato, R.K., Feldman, H.A., Hamdy, O., et al. (2000) Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care, 23, 490-494. (Pubitemid 30185792)
5. Kapoor, D., Goodwin, E., Channer, K.S., et al. (2006) Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology, 154, 899-906. (Pubitemid 43997730)
6. Khaw, K.T., Dowsett, M., Folkerd, E., et al. (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation, 116, 2694-2701. (Pubitemid 350291241)
7. Jones, T.H., (2010) Testosterone deficiency: a risk factor for cardiovascular disease? Trends in Endocrinology and Metabolism, 21, 496-503.
8. Nettleship, J.E., Jones, R.D., Channer, K.S., et al. (2009) Testosterone and coronary artery disease. In:, T.H. Jones, ed. Advances in the Management of Testosterone Deficiency. Karger, Basel, 91-107.
9. Zimmet, P., Magliano, D., Matsuzawa, Y., et al. (2005) The metabolic syndrome: a global public health problem and a new definition. Journal of Atherosclerosis and Thrombosis, 12, 295-300.
10. Simon, D., Charles, M.A., Nahoul, K., et al. (1997) Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. Journal of Clinical Endocrinology and Metabolism, 82, 682-685. (Pubitemid 27068651)
11. Haffner, S.M., Laakso, M., Miettinen, H., et al. (1996) Low levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoprotein in normoglycemic men. Journal of Clinical Endocrinology and Metabolism, 81, 3697-3701. (Pubitemid 26339941)
12. Van Pottelbergh, I., Braeckman, L., De Bacquer, D., et al. (2003) Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis, 166, 95-102. (Pubitemid 35449605)
13. Isidori, A.M., Giannetta, E., Greco, E.A., et al. (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clinical Endocrinology (Oxford), 63, 280-293. (Pubitemid 41233445)
14. Whitsel, E.A., Boyko, E.J., Matsumoto, A.M., et al. (2001) Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. American Journal of Medicine, 111, 261-269. (Pubitemid 32885620)
15. Chamberlain, N.L., Driver, E.D., &, Miesfeld, R.L., (1994) The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Research, 22, 3181-3186. (Pubitemid 24260654)
16. Zitzmann, M., &, Nieschlag, E., (2003) The CAG repeat polymorphism within the androgen receptor gene and maleness. International Journal of Andrology, 26, 76-83. (Pubitemid 36408236)
17. Stanworth, R.D., Kapoor, D., Channer, K.S., et al. (2008) Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. European Journal of Endocrinology, 159, 739-746.
18. Tremblay, R.R., &, Dube, J.Y., (1974) Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception, 10, 599-605.
19. Vermeulen, A., Rubens, R., &, Verdonck, L., (1972) Testosterone secretion and metabolism in male senescence. Journal of Clinical Endocrinology and Metabolism, 34, 730-735.
20. Platz, E.A., Rimm, E.B., Willett, W.C., et al. (2000) Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. Journal of the National Cancer Institute, 92, 2009-2017. (Pubitemid 32045897)
21. Agledahl, I., Skjaerpe, P.A., Hansen, J.B., et al. (2008) Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: the Tromso study. Nutrition, Metabolism, and Cardiovascular Diseases, 18, 256-262. (Pubitemid 351707613)
22. Zitzmann, M., Brune, M., Kornmann, B., et al. (2001) The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. Journal of Clinical Endocrinology and Metabolism, 86, 4867-4873. (Pubitemid 33020534)
23. Hall, J., Jones, R.D., Jones, T.H., et al. (2006) Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology, 147, 2675-2680. (Pubitemid 43764603)
24. Guo, Z., Benten, W.P., Krucken, J., et al. (2002) Nongenomic testosterone calcium signaling. Genotropic actions in androgen receptor-free macrophages. The Journal of Biological Chemistry, 277, 29600-29607. (Pubitemid 41079249)
25. Nettleship, J.E., Jones, T.H., Channer, K.S., et al. (2007) Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation, 116, 2427-2434. (Pubitemid 350145077)
26. Malkin, C.J., Pugh, P.J., Jones, R.D., et al. (2004) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 89, 3313-3318. (Pubitemid 38951897)
27. Stanworth, R.D., Kapoor, D., Channer, K.S., et al. (2009) Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes. Diabetes Care, 32, 541-546.
28. Minnemann, T., Schubert, M., Freude, S., et al. (2008) Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. Journal of Endocrinological Investigation, 31, 718-723.
29. Laughlin, G.A., Barrett-Connor, E., &, Bergstrom, J., (2008) Low serum testosterone and mortality in older men. Journal of Clinical Endocrinology and Metabolism, 93, 68-75.
30. Tivesten, A., Vandenput, L., Labrie, F., et al. (2009) Low serum testosterone and estradiol predict mortality in elderly men. Journal of Clinical Endocrinology and Metabolism, 94, 2482-2488.
31. Basaria, S., Coviello, A.D., Travison, T.G., et al. (2010) Adverse events associated with testosterone administration. New England Journal of Medicine, 363, 109-122.